Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Uppsala, Sweden.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E, undervalued on EV/EBITDA, underpric
Target Price
The average target price of AROC.ST is 0.80 and suggests 39% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell